CE Mark Odds, page-19

Well China Grandpharm reports mammoth profit growth since taking over Sirtex, and I think its likely Pierce Chow and his colleagues will continue to use it, since they select their patients and know how to use it to best advantage. But then they have enormous experience and being based in Singapore the majority of their Hepatocellular Ca patients are likely to be the result of Hep B and to be good responders to SIRT. The new owners are likely to be seeking approval to use it in China. I recall at the conference Pierce Chow mentioned a patient that he had to operate on early because after SIRT the tumour shrank so fast that he was worried he woudn't be able to find the remnants to accurately resect it. Thats still important because the cancer stem cells will remain and need to be surgically resected for cure.

I would say also that those physicians, radiologists and surgeons who have had good success with SIRT in the past will continue to use it. They will probably make use of the information gathered from the trials to refine their approach to RHS/LHS colon tumors and Hep B/C Liver cancer. I don't know whether Sirtex will sponsor any more trials, but there is nothing stopping individual physicians and surgeons from doing trials themselves and publishing the results. I would think its a fertile ground for investigation now that Sirtex have pointed out the way.

Quite likely Oncosil's treatment does work to some degree. But working out which patients are responders and proving it could be a mine field, just as it was for Sirtex.